Evidence map›Paper›PMID 34112845›Full record

ArticleScientific reports2021

High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation.

Laura Sibley, Andrew D White, Karen E Gooch, Lisa M Stevens, Rachel Tanner, Ashley Jacobs, Owen Daykin-Pont, Fergus Gleeson, Anthony McIntyre, Randall Basaraba and 9 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Laura SibleyNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK. laura.sibley@phe.gov.uk.
Andrew D WhiteNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Karen E GoochNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Lisa M StevensNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Rachel TannerNuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, UK.
Ashley JacobsUniversity of Cape Town, Cape Town, South Africa.
Owen Daykin-PontNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Fergus GleesonChurchill Hospital, Headington, Oxford, UK.
Anthony McIntyreChurchill Hospital, Headington, Oxford, UK.
Randall BasarabaColorado State University, Fort Collins, CO, USA.
Simon ClarkNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Graham HallNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Geoff PearsonNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Emma RaynerNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Helen McShaneNuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, UK.
Ann WilliamsNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Mike DennisNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Philip D MarshNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Sally SharpeNational Infection Service, Public Health England, Porton Down, Wiltshire, SP4 0JG, UK.
Public Health England · GBChurchill Hospital · GBColorado State University · USJenner Institute · GBUniversity of Cape Town · ZAUniversity of Oxford · GB

Funding

Department of Health
6 · The paper itself

Abstract

This study describes the use of cynomolgus macaques of Chinese origin (CCM) to evaluate the efficacy and immunogenicity of the BCG vaccine against high dose aerosol Mycobacterium tuberculosis challenge. Progressive disease developed in three of the unvaccinated animals within 10 weeks of challenge, whereas all six vaccinated animals controlled disease for 26 weeks. Three unvaccinated animals limited disease progression, highlighting the intrinsic ability of this macaque species to control disease in comparison to macaques of other species and genotypes. Low levels of IFNγ were induced by BCG vaccination in CCM suggesting that IFNγ alone does not provide a sufficiently sensitive biomarker of vaccination in this model. An early response after challenge, together with the natural bias towards terminal effector memory T-cell populations and the contribution of monocytes appears to enhance the ability of CCM to naturally control infection. The high dose aerosol challenge model of CCM has value for examination of the host immune system to characterise control of infection which would influence future vaccine design. Although it may not be the preferred platform for the assessment of prophylactic vaccine candidates, the model could be well suited for testing post-exposure vaccination strategies and drug evaluation studies.

Indexed as

Administration, InhalationAnimalsBCG VaccineCytokinesDisease Models, AnimalDisease ProgressionHost-Pathogen InteractionsImmunity, HumoralImmunizationImmunologic MemoryMacacaMaleMycobacterium tuberculosisT-Lymphocyte SubsetsTuberculosisBCG VaccineCytokines

Identifiers

PMID34112845
PMCPMC8192909
OpenAlexW3170334798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.